Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma

(MedPage Today) — Good survival outcomes, but high rates of toxicities, with ipilimumab-nivolumab combo Source: Dermatology

(MedPage Today) — Good survival outcomes, but high rates of toxicities, with ipilimumab-nivolumab combo
Source: Dermatology

Leave a Reply